caa a22 4500 469073853 CHVBK 20180323132929.0 cr unu---uuuuu 170328e19920701xx s 000 0 eng 10.1007/BF01789332 doi (NATIONALLICENCE)springer-10.1007/BF01789332 Effects of tumor necrosis factor α, interferon α and interferon γ on non-lymphoid leukemia cell lines: Growth inhibition, differentiation induction and drug sensitivity modulation [Elektronische Daten] [Akira Kikuchi, Vladimir Holáň, Jun Minowada] Summary: The potential role of tumor necrosis factor α (TNFα), interferon α (IFNα) and interferon γ (IFNγ) in the therapy of non-lymphoid leukemia was studied in ten non-lymphoid leukemia cell lines. All three cytokines tested inhibited the growth of the cell lines. However, a high degree of variability in susceptibility to cytotoxic/cytostatic effect of the cytokines was found among individual cell lines. Some cell lines were sensitive to the antiproliferative action of only one of the cytokines tested, but were resistant to the others. Combinations of two cytokines had additive or synergistic effects and inhibited cell growth to a greater extent than did the individual cytokines alone. In addition to the growth-inhibitory effect, the cytokines induced an apparent cell differentiation. The differentiation of the two most sensitive cell lines, EoL-1 and PL-21, was confirmed using the nitroblue tetrazolium reduction test, by changes in cell morphology, immunophenotype marker profiles and by changes in c-myb expression. Furthermore, we showed that even in the cell lines relatively resistant to the antiproliferative effect of cytokines, such as cell line KCL-22, the inhibition of cell growth could be markedly increased with the DNA-topoisomerase-II-targeted drug, doxorubicin. Our data thus suggest that TNFα, IFNα and IFNγ together have a potential role in the immunotherapy of non-lymphoid leukemia in terms of their antiproliferative action, and their ability to induce differentiation and to modulate drug sensitivity. Springer-Verlag, 1992 Non-lymphoid leukemia nationallicence Cytokines nationallicence Immunotherapy nationallicence Kikuchi Akira Fujisaki Cell Center, Hayashibara Biochemical Laboratories Inc., 675-1 Fujisaki, 702, Okayama, Japan aut Holáň Vladimir Fujisaki Cell Center, Hayashibara Biochemical Laboratories Inc., 675-1 Fujisaki, 702, Okayama, Japan aut Minowada Jun Fujisaki Cell Center, Hayashibara Biochemical Laboratories Inc., 675-1 Fujisaki, 702, Okayama, Japan aut Cancer Immunology, Immunotherapy Springer-Verlag 35/4(1992-07-01), 257-263 0340-7004 35:4<257 1992 35 262 https://doi.org/10.1007/BF01789332 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF01789332 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Kikuchi Akira Fujisaki Cell Center, Hayashibara Biochemical Laboratories Inc., 675-1 Fujisaki, 702, Okayama, Japan aut NATIONALLICENCE 700 1- Holáň Vladimir Fujisaki Cell Center, Hayashibara Biochemical Laboratories Inc., 675-1 Fujisaki, 702, Okayama, Japan aut NATIONALLICENCE 700 1- Minowada Jun Fujisaki Cell Center, Hayashibara Biochemical Laboratories Inc., 675-1 Fujisaki, 702, Okayama, Japan aut NATIONALLICENCE 773 0- Cancer Immunology, Immunotherapy Springer-Verlag 35/4(1992-07-01), 257-263 0340-7004 35:4<257 1992 35 262 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer